APPLE News
Liver Cancer 2023;12:188 –188 (Source: Liver Cancer)
Source: Liver Cancer - April 25, 2023 Category: Cancer & Oncology Source Type: research

Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management
Background Combined hepatocellular-cholangiocarcinoma (cHCC-iCCA) is a rare type of primary liver cancer displaying characteristics of both hepatocytic and cholangiocytic differentiation. Summary Because of its aggressive nature, patients with cHCC-iCCA exhibit a poorer prognosis than those with HCC. Surgical resection and liver transplantation may be considered as curative treatment approaches; however, only a minority of patients are eligible at the time of diagnosis and postoperative recurrence rates are high. For cases that are not eligible for surgery, locoregional and systemic therapy are often administered based ...
Source: Liver Cancer - April 24, 2023 Category: Cancer & Oncology Source Type: research

HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-related HCC with distinct features
Conclusion: A simple and robust genetic classification was developed to aid in understanding HBV-HCC and in harmonizing clinical studies. (Source: Liver Cancer)
Source: Liver Cancer - April 17, 2023 Category: Cancer & Oncology Source Type: research

Real-time fluorescence imaging to identify cholangiocarcinoma in the extrahepatic biliary tree using an enzyme-activatable probe
Conclusion Fluorescence imaging with PM-2MeSiR, which may be activated by puromycin-sensitive aminopeptidase, yielded generally high accuracy. This technique may be useful for real-time identification of the spread of eCCA during surgery and endoscopic examinations. (Source: Liver Cancer)
Source: Liver Cancer - April 14, 2023 Category: Cancer & Oncology Source Type: research

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Background: Primary liver cancer, around 75% –85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Prim ary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be u...
Source: Liver Cancer - April 5, 2023 Category: Cancer & Oncology Source Type: research

TACE for treatment-naive HCC has different treatment effects depending on central or peripheral tumor-location
Introduction: The purpose of this study was to evaluate the treatment efficacy of transcatheter arterial chemo-embolization (TACE) for treatment-naive hepatocellular carcinoma (HCC) according to tumor location and burden. Methods: Between 2010 and 2019, consecutive patients who underwent TACE as the first treatment were enrolled. Tumors were classified into two categories based on their location, as central or peripheral tumors. Tumors in the central zone, which is within 1 cm of the main trunk or the first branch of the portal vein, were classified as central tumors, while those located in the peripheral zone were classi...
Source: Liver Cancer - March 31, 2023 Category: Cancer & Oncology Source Type: research

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials
Background: Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-to-event estimates of survival outcomes for sorafenib in advanced HCC. Summary: In this systematic review and individual patient data meta-analysis of randomized-controlled trials (RCTs), we searched MEDLINE and Embase from inception till September 2022 for RCTs that provided data for overall survival (OS) and progression-free survival (PFS) for sorafenib monotherapy as first-line systemic therapy for advanced HCC. We performed a pooled analysis u...
Source: Liver Cancer - March 28, 2023 Category: Cancer & Oncology Source Type: research

Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor
Conclusion: The genomic and immunohistochemical analysis showed th at TGFBR2 mutation, loss of HLA B44 supertype, carrying B62 supertype, and increased PD-L1+ cells, macrophages and Tregs in the tumor microenvironment might be related to the non-sustain benefit of ICIs in this MSI-H patient. (Source: Liver Cancer)
Source: Liver Cancer - March 28, 2023 Category: Cancer & Oncology Source Type: research

Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma
(Source: Liver Cancer)
Source: Liver Cancer - March 23, 2023 Category: Cancer & Oncology Source Type: research